| pubmed-article:16641896 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16641896 | lifeskim:mentions | umls-concept:C0699791 | lld:lifeskim |
| pubmed-article:16641896 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:16641896 | lifeskim:mentions | umls-concept:C0123931 | lld:lifeskim |
| pubmed-article:16641896 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
| pubmed-article:16641896 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:16641896 | lifeskim:mentions | umls-concept:C1521750 | lld:lifeskim |
| pubmed-article:16641896 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:16641896 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:16641896 | pubmed:dateCreated | 2006-5-17 | lld:pubmed |
| pubmed-article:16641896 | pubmed:abstractText | The current treatment for metastatic gastric cancer (MGC) consists of cisplatin and/or fluorouracil (5-FU) based combination chemotherapy, but cisplatin-based regimens are associated with considerable toxicity. We evaluated the efficacy and safety of a noncisplatin-, non-5-FU-containing regimen, docetaxel/irinotecan in MGC. Chemo-naive patients with MGC received docetaxel (30 mg m(-2)) and irinotecan (70 mg m(-2)) on days 1 and 8 every 3 weeks. The 48 eligible patients (median age 56 years) received a median of four cycles of docetaxel/irinotecan (range 1-18). Of the 46 patients in whom efficacy could be evaluated, 21 showed a partial response (response rate=45.7%; 95% confidence interval (CI) 31.3-60.1%). At a median follow-up of 15.0 months, the median time to progression was 4.5 months (95% CI 3.8-5.2 months) and overall survival was 8.2 months (95% CI, 5.8-10.6 months). Grade 3/4 neutropenia developed in 57.4% of patients, and febrile neutropenia/neutropenic infection in 19.1%. Nonhaematological toxicities were moderate; grade 3/4 diarrhoea occurred in 19.1% of patients, however, was manageable by a dose reduction. There was one possible treatment-related death. In conclusion, weekly docetaxel/irinotecan is a promising outpatient regimen in MGC, with appropriate dose modification. | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16641896 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16641896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16641896 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16641896 | pubmed:month | May | lld:pubmed |
| pubmed-article:16641896 | pubmed:issn | 0007-0920 | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:KimY WYW | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:KimH KHK | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:LeeJ HJH | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:LeeJ SJS | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:MirJJ | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:ChoiI JIJ | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:KimC GCG | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:ParkS RSR | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:ChunJ HJH | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:RyuK WKW | lld:pubmed |
| pubmed-article:16641896 | pubmed:author | pubmed-author:BaeJ-MJM | lld:pubmed |
| pubmed-article:16641896 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16641896 | pubmed:day | 22 | lld:pubmed |
| pubmed-article:16641896 | pubmed:volume | 94 | lld:pubmed |
| pubmed-article:16641896 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16641896 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16641896 | pubmed:pagination | 1402-6 | lld:pubmed |
| pubmed-article:16641896 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:meshHeading | pubmed-meshheading:16641896... | lld:pubmed |
| pubmed-article:16641896 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16641896 | pubmed:articleTitle | Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma. | lld:pubmed |
| pubmed-article:16641896 | pubmed:affiliation | Research Institute and Hospital, National Cancer Center, 809 Madu1, Ilsan, Goyang, Gyeonggi 410-769, Republic of Korea. | lld:pubmed |
| pubmed-article:16641896 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16641896 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16641896 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16641896 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16641896 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16641896 | lld:pubmed |
